Thomas Flaig

Dr. Flaig is an active clinical and translational scientist who performed the murine experiments that led to the Phase I SBIR grant and is currently the Chair of the National Comprehensive Cancer Network (NCCN) bladder cancer guidelines panel. He serves the University of Colorado Cancer Center as the head of the Clinical Trials Office and is local PI for a number of ongoing pharmaceutical and NCI trials in bladder cancer.